In accordance with Section 28a of the Danish Securities Trading Act,
Novo Nordisk is required on a daily basis to publish trading in Novo
Nordisk shares by the company's board members, executives and their
associated persons as reported by those persons to Novo Nordisk.
Please find below a statement of such trading in shares issued by
Novo Nordisk.
+--------------------------------------------------------------+
| Name | Wedel Family Trust |
|----------------------------------+---------------------------|
| Reason for reporting | Associated to a member of |
| | The Board of Directors |
|----------------------------------+---------------------------|
| Financial instrument and ID code | NVO |
|----------------------------------+---------------------------|
| Type of transaction | Purchase of ADRs |
|----------------------------------+---------------------------|
| Date of transaction | 1 February 2008 |
|----------------------------------+---------------------------|
| Place of transaction | New York Stock Exchange |
|----------------------------------+---------------------------|
| Volume of transaction | 3,000 ADRs |
|----------------------------------+---------------------------|
| Total value of transaction | DKK 926,911 |
+--------------------------------------------------------------+
Definitions and background information:
Publication
Publication shall take place the day after Novo Nordisk receives
sufficient information on the trading. Publication is only required
when the total amount of transactions of a specific board
member/executive and his/her associated persons in any one calendar
year has reached 5,000 euros.
Who are board members, executives and associated persons?
Board members and executives are members of the Board of Directors
and Executive Management, respectively, of Novo Nordisk A/S.
Associated persons are defined as the following persons associated to
a board member/executive: 1) spouse or cohabitant, 2) children under
the age of 18 years, 3) relatives defined as brothers, sisters,
parents, grandparents etc, children, grandchildren etc who have
shared the same household with a board member/executive for at least
one year, and 4) any legal person, including a company, a foundation
or a partnership, which is controlled directly or indirectly by a
board member/executive and/or a person mentioned in 1)-3), or to
which a board member/executive and/or a person mentioned in 1)-3) has
managerial responsibilities or economic interests substantially
equivalent to the legal person.
What is trading/transaction?
Trading is any kind of transaction, including shares purchased or
otherwise acquired, shares sold or otherwise disposed, gifts,
mortgages and grants and exercise of options, but not heritage.
What is financial instrument and ID code?
Financial instrument includes shares listed on the OMX Nordic
Exchange Copenhagen and London Stock Exchange as well as ADRs listed
on New York Stock Exchange, except for ADRs held in 401(k) retirement
plan by US-based employees. The ID code is the code (ISIN
DK006010261) of the Novo Nordisk share on OMX Nordic Exchange
Copenhagen, the code (NVOB) on London Stock Exchange or the code
(NVO) on New York Stock Exchange.
What is date and place of transaction?
Date of transaction is the actual transaction date. The place of
transaction is the actual place of transaction, ie OMX Nordic
Exchange Copenhagen, London Stock Exchange or New York Stock
Exchange.
What is volume and value of transaction?
The volume of transaction is the number of shares (of DKK 1 nominal
value) or other financial instruments traded. The transaction value
is the number of shares traded multiplied by the transaction price.
The exchange rate of the Danish Central Bank (Nationalbanken) on the
date of transaction is used for calculating the transaction value in
DKK in case of shares traded on London Stock Exchange and ADRs listed
on New York Stock Exchange.
Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 26,000
employees in 80 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.
For further information please contact:
Media: Investors:
Outside North America: Outside North America:
Elin K Hansen Mads Veggerby Lausten
Tel: (+45) 4442 3450 Tel: (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com
Hans Rommer
Tel: (+45) 4442 4765
hrmm@novonordisk.com
In North America: In North America:
Sean Clements Christian Qvist Frandsen
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com cqfr@novonordisk.com
Stock Exchange Announcement no 5 / 2008